BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15883125)

  • 21. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings.
    Frank A; Lefkowitz D; Jaeger S; Gobar L; Sunderland J; Gupta N; Scott W; Mailliard J; Lynch H; Bishop J
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1495-512. PubMed ID: 7635795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Contribution of PET using FDG in the diagnosis of lung cancer--first results].
    Rubinstein R; Breuer R; Chisin R
    Harefuah; 2001 Feb; 140(2):100-3, 191. PubMed ID: 11242909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer.
    Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Dittmann H; Langen HJ; Bares R
    Lung Cancer; 2007 Feb; 55(2):165-71. PubMed ID: 17129635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer.
    Kong FM; Frey KA; Quint LE; Ten Haken RK; Hayman JA; Kessler M; Chetty IJ; Normolle D; Eisbruch A; Lawrence TS
    J Clin Oncol; 2007 Jul; 25(21):3116-23. PubMed ID: 17634490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT.
    Nahmias C; Hanna WT; Wahl LM; Long MJ; Hubner KF; Townsend DW
    J Nucl Med; 2007 May; 48(5):744-51. PubMed ID: 17475962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognosis and reevaluation of lung cancer by positron emission tomography imaging.
    Erasmus JJ; Rohren E; Swisher SG
    Proc Am Thorac Soc; 2009 Apr; 6(2):171-9. PubMed ID: 19349485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation.
    Hicks RJ; Mac Manus MP; Matthews JP; Hogg A; Binns D; Rischin D; Ball DL; Peters LJ
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):412-8. PubMed ID: 15380574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Value of positron emission tomography for lung cancer staging.
    Albes JM; Dohmen BM; Schott U; Schülen E; Wehrmann M; Ziemer G
    Eur J Surg Oncol; 2002 Feb; 28(1):55-62. PubMed ID: 11869015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case of non-small cell lung cancer with false-positive staging by positron emission tomography.
    Tomita M; Ichinari H; Tomita Y; Mine K; Iiboshi H; Kisanuki A; Shibata K
    Ann Thorac Cardiovasc Surg; 2003 Dec; 9(6):397-400. PubMed ID: 15003103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of 18F-FDG PET in assessment of response in non-small cell lung cancer.
    Hicks RJ
    J Nucl Med; 2009 May; 50 Suppl 1():31S-42S. PubMed ID: 19380411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidental findings on integrated PET/CT that do not accumulate 18F-FDG.
    Bruzzi JF; Truong MT; Marom EM; Mawlawi O; Podoloff DA; Macapinlac HA; Munden RF
    AJR Am J Roentgenol; 2006 Oct; 187(4):1116-23. PubMed ID: 16985164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Impact of computed tomography (CT) and 18F-deoxyglucose-coincidence detection emission tomography (FDG-CDET) image fusion for optimisation of conformal radiotherapy in non-small-cell lung cancers].
    Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
    Cancer Radiother; 2005 Sep; 9(5):304-15. PubMed ID: 16087377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of efficacy and clinical impact of FDG-PET on patients with potentially resectable non-small cell lung cancer].
    Borrego Dorado I; López García C; Vázquez Albertino R; Ginel Cañamaque A; Barrot Cortés E
    Rev Esp Med Nucl; 2007; 26(6):335-44. PubMed ID: 18021687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of (18)F-FDG PET on treatment strategy and 3D radiotherapy planning in non-small cell lung cancer: A prospective multicenter study.
    Pommier P; Touboul E; Chabaud S; Dussart S; Le Pechoux C; Giammarile F; Carrie C
    AJR Am J Roentgenol; 2010 Aug; 195(2):350-5. PubMed ID: 20651189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lymph node staging in lung cancer using [18F]FDG-PET.
    Halter G; Buck AK; Schirrmeister H; Aksoy E; Liewald F; Glatting G; Neumaier B; Mühling B; Nüssle-Kügele K; Hetzel M; Sunder-Plassmann L; Reske SN
    Thorac Cardiovasc Surg; 2004 Apr; 52(2):96-101. PubMed ID: 15103582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
    van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
    Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer.
    Nestle U; Kremp S; Schaefer-Schuler A; Sebastian-Welsch C; Hellwig D; Rübe C; Kirsch CM
    J Nucl Med; 2005 Aug; 46(8):1342-8. PubMed ID: 16085592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Preliminary study of 18F-FDG PET-CT in defining lymph node radiation target volume for non-small-cell lung cancer patients].
    Liu LP; Yu JM; Guo HB; Fu Z; Han AQ; Yang GR
    Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):453-6. PubMed ID: 17974282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Accuracy of positron emission tomography with fluorine-18-fluoro-deoxyglucose].
    Hellwig D; Gröschel A; Rentz K; Sybrecht GW; Kirsch CM; Ukena D
    Pneumologie; 2001 Aug; 55(8):363-6. PubMed ID: 11505287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Value of 18F-FDG PET in clinical staging of non-small-cell lung cancer].
    Liu SW; Yu JM; Xing LG
    Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):626-9. PubMed ID: 15634527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.